Etoricoxib

Alan K. Matsumoto, Paul F. Cavanaugh

Research output: Contribution to journalArticle

Abstract

Etoricoxib (Arcoxia®, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. It is a member of the COX-2-selective (coxib) class of nonsteroidal antiinflammatory drugs (NSAIDs). Extensive clinical trials have confirmed its analgesic and antiinflammatory efficacy to be at least as good as and in some cases superior to nonselective NSAIDs in a number of disease and patient treatment settings. Etoricoxib displays improved gastrointestinal safety compared with nonselective NSAIDs and has a favorable overall safety and tolerability profile. It is rapidly and completely absorbed following oral administration providing a rapid onset of action. Its long plasma half-life allows for once-daily dosing. Etoricoxib is currently approved in a number of countries for various indications including the treatment of acute pain, acute gouty arthritis, chronic low back pain, primary dysmenorrhea, and chronic treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis. In countries where it is approved, the highest recommended daily dose for chronic use is 90 mg for rheumatoid arthritis and 60 mg for osteoarthritis and chronic low back pain. The recommended daily dose for acute pain relief treatment from primary dysmenorrhea and acute gouty athritis is 120 mg. This review summarizes the published preclinical and clinical data relevant to the use of etoricoxib in clinical practice.

Original languageEnglish (US)
Pages (from-to)395-414
Number of pages20
JournalDrugs of Today
Volume40
Issue number5
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

etoricoxib
Anti-Inflammatory Agents
Dysmenorrhea
Acute Pain
Low Back Pain
Osteoarthritis
Rheumatoid Arthritis
Gouty Arthritis
Pharmaceutical Preparations
Safety
Cyclooxygenase 2 Inhibitors
Cyclooxygenase 2
Therapeutics
Signs and Symptoms
Oral Administration
Half-Life
Analgesics
Clinical Trials
Inflammation
Pain

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Etoricoxib. / Matsumoto, Alan K.; Cavanaugh, Paul F.

In: Drugs of Today, Vol. 40, No. 5, 05.2004, p. 395-414.

Research output: Contribution to journalArticle

Matsumoto, AK & Cavanaugh, PF 2004, 'Etoricoxib', Drugs of Today, vol. 40, no. 5, pp. 395-414. https://doi.org/10.1358/dot.2004.40.5.850488
Matsumoto, Alan K. ; Cavanaugh, Paul F. / Etoricoxib. In: Drugs of Today. 2004 ; Vol. 40, No. 5. pp. 395-414.
@article{4a8bbdc3939547fa82e5ae964d9ebb77,
title = "Etoricoxib",
abstract = "Etoricoxib (Arcoxia{\circledR}, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. It is a member of the COX-2-selective (coxib) class of nonsteroidal antiinflammatory drugs (NSAIDs). Extensive clinical trials have confirmed its analgesic and antiinflammatory efficacy to be at least as good as and in some cases superior to nonselective NSAIDs in a number of disease and patient treatment settings. Etoricoxib displays improved gastrointestinal safety compared with nonselective NSAIDs and has a favorable overall safety and tolerability profile. It is rapidly and completely absorbed following oral administration providing a rapid onset of action. Its long plasma half-life allows for once-daily dosing. Etoricoxib is currently approved in a number of countries for various indications including the treatment of acute pain, acute gouty arthritis, chronic low back pain, primary dysmenorrhea, and chronic treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis. In countries where it is approved, the highest recommended daily dose for chronic use is 90 mg for rheumatoid arthritis and 60 mg for osteoarthritis and chronic low back pain. The recommended daily dose for acute pain relief treatment from primary dysmenorrhea and acute gouty athritis is 120 mg. This review summarizes the published preclinical and clinical data relevant to the use of etoricoxib in clinical practice.",
author = "Matsumoto, {Alan K.} and Cavanaugh, {Paul F.}",
year = "2004",
month = "5",
doi = "10.1358/dot.2004.40.5.850488",
language = "English (US)",
volume = "40",
pages = "395--414",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Etoricoxib

AU - Matsumoto, Alan K.

AU - Cavanaugh, Paul F.

PY - 2004/5

Y1 - 2004/5

N2 - Etoricoxib (Arcoxia®, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. It is a member of the COX-2-selective (coxib) class of nonsteroidal antiinflammatory drugs (NSAIDs). Extensive clinical trials have confirmed its analgesic and antiinflammatory efficacy to be at least as good as and in some cases superior to nonselective NSAIDs in a number of disease and patient treatment settings. Etoricoxib displays improved gastrointestinal safety compared with nonselective NSAIDs and has a favorable overall safety and tolerability profile. It is rapidly and completely absorbed following oral administration providing a rapid onset of action. Its long plasma half-life allows for once-daily dosing. Etoricoxib is currently approved in a number of countries for various indications including the treatment of acute pain, acute gouty arthritis, chronic low back pain, primary dysmenorrhea, and chronic treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis. In countries where it is approved, the highest recommended daily dose for chronic use is 90 mg for rheumatoid arthritis and 60 mg for osteoarthritis and chronic low back pain. The recommended daily dose for acute pain relief treatment from primary dysmenorrhea and acute gouty athritis is 120 mg. This review summarizes the published preclinical and clinical data relevant to the use of etoricoxib in clinical practice.

AB - Etoricoxib (Arcoxia®, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. It is a member of the COX-2-selective (coxib) class of nonsteroidal antiinflammatory drugs (NSAIDs). Extensive clinical trials have confirmed its analgesic and antiinflammatory efficacy to be at least as good as and in some cases superior to nonselective NSAIDs in a number of disease and patient treatment settings. Etoricoxib displays improved gastrointestinal safety compared with nonselective NSAIDs and has a favorable overall safety and tolerability profile. It is rapidly and completely absorbed following oral administration providing a rapid onset of action. Its long plasma half-life allows for once-daily dosing. Etoricoxib is currently approved in a number of countries for various indications including the treatment of acute pain, acute gouty arthritis, chronic low back pain, primary dysmenorrhea, and chronic treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis. In countries where it is approved, the highest recommended daily dose for chronic use is 90 mg for rheumatoid arthritis and 60 mg for osteoarthritis and chronic low back pain. The recommended daily dose for acute pain relief treatment from primary dysmenorrhea and acute gouty athritis is 120 mg. This review summarizes the published preclinical and clinical data relevant to the use of etoricoxib in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=3042780168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042780168&partnerID=8YFLogxK

U2 - 10.1358/dot.2004.40.5.850488

DO - 10.1358/dot.2004.40.5.850488

M3 - Article

VL - 40

SP - 395

EP - 414

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 5

ER -